Slide 1: Exchange filing cover letter
08 August 2025 To To National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Dalal Street Complex, Bandra (E), Mumbai – 400 051 Mumbai – 400001 NSE Scrip Symbol: SaiLife BSE Scrip Code: 544306 Sub: Investor Presentation for the quart
Slide 2: Sai Life Sciences Limited Investor Presentation
Sai Life Sciences Limited Investor Presentation August 08, 2025
Slide 3: Safe Harbour
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: The CRDMO industry is a Service Business with value drivers different from generic pharma
The CRDMO industry is a Service Business with value drivers different from generic pharma companies • R&D investments in drug discovery / development program translate to revenue “As a CRDMO, our value doesn’t hinge on opportunities for CRDMOs – irrespective of whether it receives approval or not •
Slide 5: Executive Summary
“ Sai Make it better together Executive Summary
Slide 6: Message from Managing Director & CEO
Message from Managing Director & CEO “ We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development and Commercial Manufacturing businesses. This momentum reflects the growing trust and deepening engagement we share with our global pharma clients' relation
Slide 7: Message from Chief Financial Officer
Message from Chief Financial Officer “ We are pleased to report a robust performance for Q1FY26, marked by strong growth across our Discovery and CDMO businesses. Total revenue for the quarter stood at ₹496 Cr, up 77% YoY, led by 113% growth in CDMO and a 38% rise in Discovery, enabled by deeper eng
Slide 8: Q1FY26 Business Highlights
Q1FY26 Business Highlights Infrastructure & Capacity Expansion • Commenced commercial operations at Bidar (PB-11 Phase II), adding ~91 KL capacity and taking the total manufacturing capacity to ~700 KL • Inaugurated Peptide Research Center at Hyderabad R&D campus, strengthening capabilities in compl
Slide 9: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue (₹ Cr) Material Margin (₹ Cr) and Margin (%) EBITDA (₹ Cr) and Margin (%) PAT (₹ Cr) and Margin (%) 74% 25% 12% 72% 496 60 355 125 207 11% 280 31 -13 -5% Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY26 Revenue Contribution • Revenue for Q1FY26
Slide 10: Sustained Growth Momentum with Expanding Profitability
Sustained Growth Momentum with Expanding Profitability (Consolidated) 25% 25% 20% 11% Positioned to 15% 15% achieve 15-20% 1,695 revenue CAGR over 1,465 1,217 3-5 years, 28 - 30% 870 EBITDA margins over the next 2-3 496 280 years FY22 FY23 FY24 FY25 Q1FY25 Q1FY26 IPO Revenue (₹ Cr) EBITDA Margin (%)
Slide 11: Company Overview
“ Sai Make it better together Company Overview
Slide 12: Sai Life Sciences: At a Glance
Sai Life Sciences: At a Glance 25+ Years of Expertise Global Partner of Choice Expansive Infrastructure Innovation-Led Growth Founded in 1999, Sai Life Trusted by 300+ global clients, World-class R&D and Focused investments in next- Sciences has transformed into including 18 of the top 25 global man
Slide 13: Key Highlights
Key Highlights One-stop 25+ platform 3,400+ 300+ Years of experience for discovery, Total employees Active customers across US, UK, EU, (Incorporated in 1999) development and manufacturing Japan USFDA, PMDA Diverse 10+ 100% successful track record of therapy areas 18/25 Oncology, CNS, Inflammation,
Slide 14: Global Presence
Global Presence Research laboratories for discovery and development located near overseas innovation hubs in Greater Boston, US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India Sai Facilities Presence Process R&
Slide 15: Our Growth Journey
Our Growth Journey 1999 - 2008 2009 – 2013 2014 – 2018 2019 – 2023 2024 – Present Founding & CDMO Consolidation of Globalization, Scaled-up Increasing Capacity & Early Biotech Foray Pivot CDMO Capabilities Integrated CRDMO Strengthening New-Age Modalities • Incorporated in 1999; began as a • First U
Slide 16: A leading CRDMO with scaled operations across both verticals
A leading CRDMO with scaled operations across both verticals Sai Life Sciences operates as both a CRO and a CDMO, offering an end-to-end platform for global pharmaceutical and biotech companies Phase 1 Phase 2 Phase 3 Seamless Integration – One-stop solution from research to DISCOVERY DEVELOPMENT MA
Slide 17: Discovery Services (CRO)
Discovery Services (CRO) Consistent Revenue Growth (₹ Cr) 626 497 Client Stickiness Dedicated Facility Modalities Expansion 467 274 189 >65% Revenues from Among the few CROs Expanding capabilities customers in FY23-25 with a dedicated facility in ADCs, TPDs, FY21 FY22 FY23 FY24 FY25 who availed more
Slide 18: Discovery Services: Scaling Innovation, Driving Impact
Discovery Services: Scaling Innovation, Driving Impact >65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes Expanded Core Colocalized & Tech-Enabled Drug Specialized Next-Gen Capabilities Global Teams Di
Slide 19: CMC Services (CDMO)
CMC Services (CDMO) • End-to-End capabilities from IND through to commercialization Consistent Revenue Growth (₹ Cr) • Focus on Complex Chemistry, ADC Payloads & Linkers • Modern, GMP-compliant facilities across UK and India • Flexibility to support both small-scale clinical supplies and large-scale
Slide 20: New Modalities: Fortifying foundation to build scale
New Modalities: Fortifying foundation to build scale Peptides Antibody-Drug Conjugates Complement peptide discovery with Enhancing conjugation in Discovery; New Modalities Revenue Contribution (%) upgrading to class 6 containment for process and scale-up facilities for clinical supplies; focus on co
Slide 21: Our Strengths
“ Sai Make it better together Our Strengths
Slide 22: Strategic Growth Levers & Competitive Edge
Strategic Growth Levers & Competitive Edge Expanding Capacity & Technology-Driven Talent & Innovation Capabilities Efficiency Culture Deeper Customer Global Footprint, Local Quality & Sustainability Engagement Advantage Leadership 21
Slide 23: Information Technology - Driven Excellence: Digitization & Beyond
Information Technology - Driven Excellence: Digitization & Beyond Digitization Digitalization Digital Transformation 2017 onwards 2022 onwards 2023 onwards Converting data, documents and processes Use of digitized data for effective monitoring integration of digital technologies into all from paper/
Slide 24: Global-Standard Operations, End-to-End
Global-Standard Operations, End-to-End Quality Assurance Sustainability Leadership Safety & EHS Leadership • 285+ QA/QC professionals • 89% renewable energy at Bidar • Embedded Process Safety from across sites site quote to execution phase; • Integrated e-systems: LIMS, e- • Zero Liquid Discharge: w
Slide 25: Key Drivers for Growth
Key Drivers for Growth Scaling Capacity & Infrastructure Diversifying Portfolio Scientific & Talent Leadership • The company continue to make strategic • 36 active molecules* –30 commercial, • Driving global program transfers to India capital investments in line with its annual with 6 Phase III / pr
Slide 26: Industry Overview
“ Sai Make it better together Industry Overview
Slide 27: Global CRDMO Industry Set to Cross USD 300 Bn by 2028
Global CRDMO Industry Set to Cross USD 300 Bn by 2028 Global CRDMO Market (USD Bn) Global CRDMO Market by Modality (USD Bn) With growing investments 303 in biologics, peptides, and 77 196 new modalities, Sai Life 44 Large molecule Sciences is positioned to 127 Small molecule 21 225 capture growth in
Slide 28: India Rising as a Strategic CRDMO Hub
India Rising as a Strategic CRDMO Hub Indian CRDMO Market (USD Bn) Global CRDMO Market by Modality (USD Bn) Sai Life Sciences is 14 1 scaling capacity, innovation, and specialty 7 Large molecule modalities to leverage 1 13 Small molecule 4 India’s rising global 0 7 4 CRDMO share and China- to-India
Slide 29: Annexure
“ Sai Make it better together Annexure
Slide 30: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss Particulars (₹ Cr) Q1FY26 Q1FY25 Q4FY25 FY25 FY24 Revenue from operations 496 280 580 1695 1465 Other income 10 8 6 18 14 Total income 506 288 586 1712 1494 Expenses Cost of materials consumed and changes in inventories 141 73 168 466 446 Employee benefits e
Slide 31: Glossary
Glossary APIs Active pharmaceutical ingredients Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug Biotechs development technologies to address unmet medical needs Blockbuste
Slide 32: Thank You
Thank You For more details please contact: Investorrelation@sailife.com © Sai Life Sciences Limited. L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.